Japan Opportunity Assessment


US-based biotech company developing phase II product in US/EU, trying to assess whether to expand development activities into Japan now or later.
In planning for an IPO in a few months time, the company needed to ensure that investors understood the true global value of their product.


Understand Japanese market landscape for a severe, rare disease with only about 3,000 patients. Obtain feedback on product profile for multiple scenarios from KOLs in the pediatrician community in Japan.

Project Summary

  • Analyzed market data and projected demand for drugs in the same category.
  • Interviewed KOLs regarding opinions and preferences about product profiles. Identified product attribute with competitive advantage.
  • Provided comprehensive estimation of NHI price for product developed in rare but debilitating disease space.
    Suggested optimal development strategy for best price to maximize enterprise value of product.
  • Proposed local clinical development strategies aligned with global program and meeting local regulatory

Client Feedback

Client was satisfied with our detailed evidence-based work. Our timelines met their need to quickly deliver valuation of their product to the investor community.


12 weeks

Key Project Capabilities

  • Demand Analysis
  • Pricing and Market Access Consultation
  • Market Research
  • P&L Forecast/Valuation
  • Clinical Development Consultation


  • Excel-based forecasting model
    Multiple scenarios
    Reflects competitive landscape
    Evidence/fact-based time series analysis using cutting edge algorithms
  • PowerPoint presentation
    KOL comments, candid opinions about new product, minimal translation/process loss

Clear optimal development strategy and projection of product incremental value in Japan

We help non-Japanese pharma/biotech companies
understand and expand into the Japanese market.